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Abstract
Background: Limitations of the clinical efficacy of dendritic cell (DC)-based immunotherapy, as well as difficulties in their
industrial production, are largely related to the limited number of autologous DCs from each patient. We here established a
possible breakthrough, a simple and cytokine-based culture method to realize a log-scale order of functional murine DCs
(.1,000-fold), which cells were used as a model before moving to human studies.
Methodology/Principal Findings: Floating cultivation of lineage-negative hematopoietic progenitors from bone marrow in
an optimized cytokine cocktail (FLT3-L, IL-3, IL-6, and SCF) led to a stable log-scale proliferation of these cells, and a
subsequent differentiation study using IL-4/GM-CSF revealed that 3-weeks of expansion was optimal to produce CD11b
+/
CD11c
+ DC-like cells. The expanded DCs had typical features of conventional myeloid DCs in vitro and in vivo, including
identical efficacy as tumor vaccines.
Conclusions/Significance: The concept of DC expansion should make a significant contribution to the progress of DC-
based immunotherapy.
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Introduction
Dendritic cells (DCs) are unique antigen-presenting cells that
can efficiently stimulate innate as well as acquired immune
responses against pathogens and endogenous cancers. Over the
last decade, there has been much anticipation about the potential
for DC-based immunotherapy as a new therapeutic modality for
cancers and infectious diseases; however, relatively limited
efficacies have been reported in clinical studies [1]. Before DC-
immunotherapy can be standardized, it will be necessary to resolve
complex issues related to the overabundance of variables in the
current clinical studies [2], including DC subtypes, antigen
targeting in vivo, doses of DCs, and so on. Among these
parameters, a possible critical issue underlying DC-immunother-
apy is that only a limited numbers of DCs (roughly 10
6 to 10
8 DCs)
are available from each patient in clinical studies, even via
frequent aphereses for DC progenitor collection. Therefore, it is
clear that the establishment of technology to expand the number
of DCs would make the process of DC manipulation less invasive
and would facilitate quality control in the industrial production of
DCs. More importantly, experimental studies using dermal tumor
and lung metastasis models have revealed that DC-based
immunotherapy elicited a significant dose-response. The optimal
dose for both models was at least 10
6 DCs/30 g, roughly
equivalent to 10
9 DCs/patient according to the weight ratio
(Kato T, Ueda Y, Yonemitsu Y, et al., unpublished data).
Therefore, increasing the number of DCs would be expected to
improve the efficacy of DC-based immunotherapy in a clinical
setting. For these reasons, we here focused on the development of
a technique for expanding functional murine DCs from bone
marrow as a first step before moving to human materials.
Results
Lineage-negative hematopoietic progenitors (HPs: CD45R
2,
CD5
2, CD11b
2, Gr-1
2, TER119
2, 7/4
2) were prepared from
bone marrow cells of female C3H/HeN as previously described
[3,4], and cultivated for 6 weeks under each cytokine (FLT3-L:
FLT3-ligand; SCF: stem cell factor; IL-3: interleukin-3 or IL-6)
that were previously shown to expand HPs [5–7], or their mixture
(abbreviated as FS36) to assess their ability to expand the
progenitor cells.
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6, could expand HPs, a finding in agreement with those of
previous reports [5,6], over 10 days after floating cultivation in a
low cell binding plate (Fig. 1a). The mixture of these cytokines, on
the other hand, showed a more pronounced cell expansion; a
nearly 2-log higher number of cells was found when FS36 was
used, compared to that seen with IL-3, at 3 weeks. Finally, more
than 10
12 cells could be obtained from 10
5 HPs (=10
7-fold
expansion) after 6 weeks of cultivation; therefore, we focused on
the FS36 cytokine mixture. This experiment was repeated at least
three times using female C3H/He mice, and representative results
were also obtained using male C3H/He mice, female balb/c mice
and C57BL6J mice (data not shown).
We next moved to a study assessing the yield of immature DCs
from expanded progenitors. One-week cultivation under GM-
CSF/IL-4 led HPs without expansion to CD11c
+CD11b
+ DCs
efficiently, and similar findings were seen in the case of cells
expanded for 1 or 3 weeks (Fig. 1b, middle 2 panels). However, the
efficacy of the induction of CD11c
+CD11b
+ DC-like cells was
dramatically decreased when HPs expanded for 4 weeks were
used, with almost no such cells being obtained after 6 weeks of
cultivation. Scatter plots demonstrated an increasing population of
undefined cells which was gated by R1 during expansion (Fig. 1b,
left panels); therefore, we characterized these cells by assessing the
expression of surface markers. As shown in 2-panels in right of
Fig. 1b and Fig. 1c, R1-gated cells were largely composed of c-
KIT
+/CD131
+(a receptor for GM-CSF/IL-3) cells, suggesting
more dedifferentiated hematopoietic cells [8] including granulo
macrophage progenitors (GMP) [9,10]; this hypothesis was
supported by the result of an in vitro colony formation assay,
which demonstrated increased numbers of CFU-c, but not
formation of BFU-E (data not shown). We could obtained about
5,000 DCs from 100 HPs using conventional method. The yielded
CD11c
+CD11b
+ DC-like cells was optimized by the use of HPs
that had been expanded for 3 weeks, which resulted in a more
than 1,000-fold increase in cells (approximately 7,000,000
CD11c
+CD11b
+ DC-like cells from 100 HPs) (Fig. 1d). Further
FACS studies demonstrated that yielded CD11c
+CD11b
+ DC-like
cells were negative for B220 (data not shown), suggesting that these
cells were not plasmacytoid DCs.
Next, we assessed whether CD11c
+CD11b
+ DC-like cells
(expanded DCs) obtained from HPs after 3 weeks of expansion
by FS36 might have typical features of myeloid DCs produced via
a conventional culture method (conventional DCs) [3,4]. As shown
in Fig. 2a, both types of DCs demonstrated typical dendrites under
a microscope at two days after culture in a medium containing
lipopolysaccharide (LPS: 1 mg/ml). FACS analyses also showed
the expression of typical surface markers of both DCs (CD40,
CD80, CD86, MHC class II, and CCR7), although the expression
level of each antigen varied between conventional DCs and
expanded DCs (conventional DCs . expanded DCs: CD40,
conventional DCs=expanded DCs: CCR7, and conventional
DCs , expanded DCs: CD80, CD86 and MHC class II) (Fig. 2b).
The expression of cytokine/chemokines in response to stimulators,
including the F-gene deleted non-transmissible recombinant
Sendai virus (SeV/dF) recognized by RIG-I [4,11], LPS by
Toll-like receptor 4 (TLR-4), poly I:C by TLR-3, CpG-DNA by
TLR-9, and R848 by TLR-7, was commonly seen in both types of
DCs (Fig. 2c). Among these, the responses of murine IL-12/p70
(mIL-12/p70) and mTNF-a to these stimulators were more
pronounced in expanded DC-like cells compared to those seen in
conventional DCs. These findings were basically identical to those
seen using male C3H/He mice, female balb/c mice and C57BL6J
mice (data not shown).
Next, we assessed the endo-/phagocytotic activity, a typical
feature of antigen-presenting cells such as DCs, by FITC-dextran
uptake assay. Repeated experiments demonstrated that both
unstimulated immature DCs showed a similar uptake activity that
was impaired by LPS but not by stimulation with rSeV/dF or poly
I:C, and these findings were similar to those in our previous study
[4]. The assay for the mixed leukocyte reaction (MLR) against
allogenic antigen (C57BL6J) demonstrated an alloantigen-specific
T-lymphocyte proliferation by both LPS-stimulated and unstimu-
lated DCs, suggesting that both DCs enhanced alloantigen-specific
T-cell proliferation.
The function of the immunostimulating activity of expanded
DCs was further assessed using two different syngeneic mouse
models of cancer vaccines in vivo—namely, subcutaneous inocu-
lation forming dermal tumor (major effector: cytotoxic T-
lymphocytes, or CTLs) and lung metastasis by intravenous
injection (major effector: natural killer cells, or NK cells) using
syngeneic (C3H/He) LM8 osteosarcoma [12]. We here used
rSeV/dF as a DC-stimulator, because it has been shown that DCs
treated by this modality demonstrated strongly enhanced antitu-
mor immunity in dermal [3,4] and metastatic [13] tumors. As
shown in Fig. 3c, three-times weekly prevaccination through an
intradermal route of conventional DCs treated with rSeV/dF
significantly prevented tumor formation (P,0.001). Under the
same treatment regimen, rSeV/dF-DCs that were obtained from
HPs expanded for 3 weeks also showed a similar effect; however,
rSeV/dF-treated and 3-weeks’ expanded HPs without GM-CSF/
IL-4 for DC differentiation did not show a significant antitumor
effect. When conventional DCs were administered intravenously
via the tail vein 2 days before tumor inoculation, DCs activated
either by LPS or rSeV/dF but not immature DCs significantly
prevented the lung metastasis; the effect was more pronounced
when rSeV/dF-DCs were used, as shown in Fig. 3d. The
representative findings shown in this figure were obtained in our
previous study using rat prostatic cancer AT6.3 cells [13]. Similar
results were also obtained in the present study using expanded
DCs, even those obtained from HPs after 2 weeks of expansion.
Taken together, these findings led us to conclude that cells
differentiated from expanded HPs could be considered functional
and nearly equivalent to those obtained from the conventional
method.
Discussion
The growing demand for increased numbers of functional DCs,
both for improved efficacy of DC-based immunotherapy and for
use in the industrial production of DCs, has led us to develop an
efficient method for the mass production of functional DCs. As an
important first step, we established and optimized a two-step
culture method, consisting of 3 weeks of expansion under FS36
followed by GM-CSF/IL-4, to expand murine DCs from bone
marrow more than 1,000-fold, and we believe that this technique
could be extended to human DCs. Furthermore, to the best of our
knowledge, this is the first demonstration of an efficient, more than
3-log expansion of murine functional DCs ex vivo.
Basically, there are a considerable number of studies assessing
the expansive ability of cytokines for hematopoietic series [5];
however, to our best knowledge, the first study attempting to
expand murine DCs was published in 2000 by Feng et al [6] who
used relatively complex cocktail of cytokines (GM-CSF, TNF-a,
IL-7, IL-3, SCF, and FLT3-L) and single step cultivation. It is very
difficult to make a direct comparison between this study and the
present one, because no data are available regarding the basal
number of DCs via GM-CSF/IL-4, they obtained more than 10
5
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6674Figure 1. Cytokine-based expansion of bone marrow-derived murine DCs. Bone marrow (from female C3H/He)-derived lineage-negative
cells (CD45R
2, CD5
2, CD11b
2, Gr-1
2, TER119
2, and 7/4
2) were enriched using a SpinSep mouse hematopoietic progenitor enrichment kit. These
cells were subjected to progenitor expansion by various cytokines under a floating condition in an MPC treated flask. At each time point, the culture
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3 of c-kit
low and c-kit
,low hematopoietic stem cells
(HSCs). As usual, the conventional culture method using GM-
CSF/IL-4 increases the final number of DCs from progenitors
approximately 10-fold; therefore, the expansion efficacy in their
report might be roughly estimated as ,10-fold (in other words,
100-fold lower than those obtained by our regimen). Since these
authors demonstrated that, among used cytokines, the combina-
tion of SCF and IL-3 but not FLT3-L did play a significant role in
the DC expansion, findings apparently conflicting to the expansion
of HPs suggesting the its critical role of FLT3-L [7]; therefore, it
should be necessary to select cytokines appropriately selected for
the target cell expansion.
We here demonstrated that expanded DCs showed similar
characteristics, in views of morphology, surface markers, and
biological functions, to those seen in conventional DCs. These
findings, however, do not always indicate their equivalency at each
developmental stage of a hematopoietic series. For example,
repeated gene expression analyses using a microarray system have
revealed the critical difference between conventional and expand-
ed DCs on expression in some essential genes concerning
hematopoietic differentiation was observed; i.e. GATA-1: conv.
, exp. (6.3-fold), GATA-3: conv. , exp (12.0-fold), and inversely,
GATA-2: conv. . exp (6.0-fold) (unpublished data). More
importantly, it is not likely that FS36-expanded cells might be
equivalent to monocyte-dendritic cell progenitor (MDP), which
was highly enriched in Lin
2/c-Kit
+ as well as CD115
+ (a receptor
for M-CSF) [14,15]; these expanded cells contained very small
population of defined MDPs (less than 1 %, data not shown), even
though the progenitor cells expanded by FS36 could be
differentiated into DCs. Furthermore, our colony formation assay
revealed that FS36-expanded cells couldn’t form BFU-E (data not
shown), suggesting that these cells may contain GMP rather than
common myeloid progenitor (CMP). These findings suggest that
cells showing typical and predefined features of DCs might be
involved in relatively broad range of developmental stage of
hematopoietic series. Even if this hypothesis is true, this would not
undermine the value of developing a DC expansion system,
because we believe that such a system would realize not only more
efficient therapeutic outcomes but also mass industrial production.
This raises an important question: is the cytokine cocktail used
in the current study applicable for the expansion of human DCs?
To our knowledge, there is only one published study available to
address this issue. This study used a sequential culture of CD34
+
cells in medium containing FS36 followed by an alternative
cocktail (FLT3-L, SCF, and trombopoietine) and showed a
dramatic expansion (453-fold) in the cell number of progenitors;
however, only ,1610
6 DCs were produced from 1610
5 CD34
+
cells [16]. We also confirmed this in our laboratory (unpublished),
indicating that, unlike in the case of murine DCs, FS36 would not
be the optimal combination for the expansion of human DCs. We
have recently determined an optimal combination of cytokines,
and which realized a very efficient expansion regimen (more than
10,000-fold) for human CD11b
+/CD11c
+/CD1a
2/CD14
+/
MHC class II
+/CD33
+ DCs from CD34
+ cells that are now
under investigation for further characterization.
In summary, we here reported an optimized two-step culture
method to generate highly expanded functional myeloid DCs from
murine bone marrow. The concept and technology of log-scale
expansion of functional DCs would significantly contribute not
only to improved therapeutic efficacies but also to industrial mass
production of functional autologous DCs for more efficient DC-
based immunotherapy.
Materials and Methods
Ethics Statement
All animal experiments were performed in accordance with the
approved protocols and advice of the Committee for Animals,
Recombinant DNA, and Experiments Using Infectious Pathogens
at Chiba University with respect to proper care and use of
laboratory animals, and with the Law (No. 105) and Notification
(No.6) of the Japanese Government.
Mice, cell line, and rSeV/dF
Male and female C3H/He, C57/BL6, and balb/c mice (7 weeks
old) were purchased from Shizuoka Laboratory Animal Center
(Hamamatsu, Shizuoka, Japan) and kept under specific pathogen-
free conditions. The murine osteosarcoma cell line, LM8, was
purchased from RIKEN BioResource center (Tsukuba, Ibaraki,
Japan). The preparation, recovery, titration, and storage of F-
defective and non-transmissible recombinant SeV used in this study
(SeV/dF) were performed as previously described [4,17]. The virus
yields are expressed in cell infectious units (CIU) [17,18].
Generation of expanded DCs
Conventional DCs were obtained from mouse bone marrow
precursors as described previously with minor modification [3,4].
Briefly, bone marrow cells were harvested from femurs and tibias,
and lineage antigen-positive (CD45R, CD5, CD11b, Gr-1,
TER119, 7/4) cells were removed using a SpinSep mouse
hematopoietic progenitor enrichment kit (StemCell Technologies).
For expansion, these lineage-negative cells were cultured in 20 ng/
ml murine FLT3-L, 10 ng/ml murine SCF, 10 ng/ml murine IL-
3 and 10 ng/ml murine IL-6 (FS36) in RPMI 1640 medium. The
culture was started at 5210610
4 cells/ml and serially passaged at
2.5610
5 cells/ml every 3 or 4 days. During culture, cells were not
exceeded 1.5610
6 cells/ml. Subsequently, expanded cells were
cultured under 20 ng/ml murine GM-CSF (Peprotech, London,
UK) and 20 ng/ml murine IL-4 (Peprotech) in RPMI 1640
medium. On day 4, the cultures were refreshed by adding a half
volume of culture medium supplemented with GM-CSF and IL-4
at the same concentrations. On day 7, DCs were collected and
seeded at 1610
6 cells/ml and then incubated with stimulators.
Cells were cultured on an MPC treatment 6-well plate (MD6
medium was replaced with new DC-differentiation medium (RPMI 1640 containing GM-CSF/IL-4) for 1 week. The data are expressed as the
means+SEM. a. Growth curve of hematopoietic progenitor cells (HPs). Neither FLT3-L, SCF, nor IL-6 could stimulate the growth of HPs over 10 days.
Only the use of IL-3 was associated with long-term growth, and this growth was greatly accelerated when a mixture of cytokines was used (FS36).
Note the log scale on the HP cell number. b. FACS analyses indicating the time course of the scatter plot of HPs (left row), in populations of
CD11c
+CD11b
+ cells at pre- and post-treatment with GM-CSF/IL-4 (middle two 2-center rows), and of the expression of c-Kit/CD131 (a receptor of GM-
CSF/IL-3) and CD11c/CD11b in the R1-gated increasing population indicated in SSC/FSC (right two rows at right). These experiments were performed
in triplicate, and showed similar results. c. Summary of triplicate FACS experiments representing the time course of positive cell ratios for CD11b, c-
Kit, and CD131 of expanded HPs. Note the culture duration-dependent increase of c-Kit
+ and CD131
+ HPs. d. Bar graph indicating the relative
increase of CD11b
+CD11c
+ DC-like cells produced after 1-week cultivation in GM-CSF/IL-4 using expanded HPs at various time points. The data was
gathered from three independent experiments. Note that a period of 3 weeks was [optimal][most efficient], yielding a more than 3-log increase in the
production of CD11b
+CD11c
+ DC-like cells.
doi:10.1371/journal.pone.0006674.g001
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6674Figure 2. In vitro characterization of expanded murine DCs. a. Schematic diagram of expansion/differentiation/maturation/activation
sequences and microscopic morphology of conventional and expanded DCs that were stimulated by LPS. Note that typical dendrites were found in
both DCs. b. FACS analyses assessing the expression of typical surface markers. Conventional and expanded DCs after treatment with GM-CSF/IL-4
without further stimulus were subjected to FACS analyses. c. Expression of typical murine inflammatory cytokines/chemokines of conventional (open
bars) and expanded (black bars) DCs in response to various stimuli for RIG-I helicase (rSeV) or Toll-like receptors (LPS for TLR-4, poly I:C for TLR-3, CpG-
DNA for TLR-9, and R848 for TLR-7). The upper three panels (mIL-6, mIFN-b, and mIL-12/p70) were assessed by ELISA, and contain data from three
independent experiments, and the bottom three panels (mIL-6, mMCP-1/JE, and mTNF-a) were performed using a Cytometric Bead Array (CBA)
system and show one typical result taken from three independent experiments.
doi:10.1371/journal.pone.0006674.g002
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Flow cytometric analysis
Two days after stimulation, cells (1610
5) were stained with the
following FITC-, PE-, or PE-Cy5-conjugated monoclonal anti-
bodies (mAbs): CD11b, CD11c, CD40, CD54 (ICAM-1), CD80,
CD83, CD86, CD197 (CCR7), MHC Class II (eBioscience), and
CD11c (Pharmingen, San Diego, CA). The appropriate conjugat-
ed isotype-matched IgGs were used as controls. Cells were
analyzed using a FACScalibur with CellQuest software (Becton
Dickinson, Tokyo, Japan).
Fluorescein isothiocyanate (FITC)-dextran uptake
Cells were suspended in RPMI 1640 with 10% FBS and
incubated with 1 mg/ml of FITC-dextran (M.W.=40,000; Sigma-
Aldrich, Tokyo, Japan) for 30 min under separate conditions, at
4uC and 37uC. Cells were washed with ice-cold phosphate-buffered
saline (PBS) and labeled on ice with a PE-conjugated mAb for
CD11c. The CD11c-positive mean fluorescent intensity (MFI) of
FITC was analyzed by FACScalibur. The uptake was measured at
48 h after stimulation, and was calculated as the change in MFI
between cell samples incubated at 37uCa n d4 uC.
Allogeneic mixed lymphocyte reactions (allo-MLRs)
Spleen cells were obtained from allogeneic C57/BL6 mice.
After lysing red blood cells using VersaLyse Lysing Solution
(BECKMAN COULTER, Tokyo, JAPAN), lineage antigen-
positive (CD11b, CD19, CD45R, CD49b, TER119) cells were
removed by using the SpinSep mouse CD3
+ T cell enrichment kit
(StemCell Technologies), and used as responder cells. In vitro-
generated immature conventional/expanded DCs, as well as
rSeV/dF-DCs, LPS-DCs, and Poly (I:C)-DCs stimulated on day 7,
were collected at day 9. These DCs were treated with 20 ug/ml
MitomycinC (MMC) for 1 h at 37uC and then used as stimulator
cells. Allogeneic responder cells (1610
5 cells/wells) were cultured
in triplicate in a 96-well round-bottom microplate with different
numbers of stimulator APCs (the APC-to-T cell ratios were 1:10,
1:100, and 1:1000). Cultures were maintained in a humidified
atmosphere at 37uC and 5% CO2. The thymidine analogue BrdU
was added on day 4 followed by quantitation of incorporated
BrdU after a further 2 h of culture using an ELISA-based cell
proliferation kit (BrdU colorimetric, 1647229; Roche, Mannheim,
Germany) according to the manufacturer’s protocol.
Cytokine assay
ELISA. The conventional/expanded DCs were cultured with
rSeV/dF (MOI=50), LPS (1 ug/ml), or Poly (I:C) respectively for
48 h, the RPMI1640 medium (1610
5 cells/ml) was refreshed, and
DCs were incubated for 24 h. The culture media were subjected
to the concentration of murine IL-1b, IFN-b, and IL-12p70 by
quantitative sandwich enzyme immunosorbent assay using a
mouse specific ELISA kit (Biosource, Camarillo, CA) according
to the manufacturer’s instructions.
Cytokine bead array. The same media were subjected to
the concentration of mouse IL-6, MCP-1, TNF-a by a Cytometric
Bead Array (CBA) Mouse Inflammation Kit (BD Biosciences, San
Diego, CA) using a FACScalibur and CellQuest software (Becton
Dickinson, Tokyo, Japan).
Vaccination
Skin tumor. Mice were subcutaneously vaccinated via the
left flank three times each week with 1610
6 of conventional/
expanded DCs pulsed with tumor lysate. Two days after the final
vaccination, 1610
6 LM8 cells were inoculated s.c. into the left
flank of mice. The tumor volume was assessed using microcalipers
every 3 or 4 days after the inoculation of LM8 cells according to
the formula: tumor volume (mm
3)=S
26L/2, where L and S
indicate the size in millimeters of the longest and shortest part,
respectively.
Lung metastasis. Mice were intravenously vaccinated once
with 1610
6 conventional/expanded DCs pulsed with tumor lysate
ex vivo. Two days after the vaccination, 1610
6 LM8 cells were
inoculated intravenously via the tail vein. Seventeen days after the
injection of LM8 cells, the mice were sacrificed and the metastasis
was quantified according to the number of metastatic nodules on
the surface of the lung.
Statistical analysis
All data were expressed as the means+SEM, and were evaluated
statistically by one-way ANOVA or Mann-Whitney U-test when
appropriate, respectively. The statistical significance of differences
between groups was determined using the Scheffe’s test, and values
of P,0.05 were considered statistically significant.
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